Source-grounded facts extracted from Prime Medicine, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Prime Medicine, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $49.1 million for the three months ended March 31, 2026.
“Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.”
Allan Reine was appointed as member of the Board of Directors at Prime Medicine, Inc..
“The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director”
Allan Reine was appointed as Chief Executive Officer and principal executive officer at Prime Medicine, Inc..
“the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company”
Keith Gottesdiener resigned as President, Chief Executive Officer and principal executive officer at Prime Medicine, Inc..
“Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company”
Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2024.
“today reported financial results for the first quarter ended March 31, 2024”
Prime Medicine, Inc. reported the full year ended December 31, 2023 results: net income $198.1 million.
“Net loss was $198.1 million for the year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.